Auris Medical Holding AG (EARS) Scheduled to Post Quarterly Earnings on Wednesday
Auris Medical Holding AG (NASDAQ:EARS) will be issuing its quarterly earnings data before the market opens on Wednesday, November 8th. Analysts expect the company to announce earnings of ($0.17) per share for the quarter.
Auris Medical Holding AG (NASDAQ:EARS) last posted its quarterly earnings data on Thursday, August 10th. The biotechnology company reported ($0.12) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.21) by $0.09. On average, analysts expect Auris Medical Holding AG to post $-0.68 EPS for the current fiscal year and $-0.29 EPS for the next fiscal year.
Auris Medical Holding AG (NASDAQ EARS) opened at 0.76 on Wednesday. Auris Medical Holding AG has a 1-year low of $0.60 and a 1-year high of $1.50. The stock has a 50 day moving average of $0.80 and a 200 day moving average of $0.75. The stock’s market cap is $33.69 million.
Separately, Zacks Investment Research cut Auris Medical Holding AG from a “buy” rating to a “hold” rating in a report on Wednesday, October 11th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and two have issued a buy rating to the company. Auris Medical Holding AG currently has an average rating of “Hold” and an average target price of $3.25.
TRADEMARK VIOLATION NOTICE: This news story was originally posted by American Banking News and is owned by of American Banking News. If you are viewing this news story on another website, it was illegally copied and republished in violation of US & international trademark & copyright laws. The correct version of this news story can be accessed at https://www.americanbankingnews.com/2017/11/01/auris-medical-holding-ag-ears-scheduled-to-post-quarterly-earnings-on-wednesday.html.
Auris Medical Holding AG Company Profile
Auris Medical Holding AG is a holding and clinical-stage biopharmaceutical company focused on the development of products for the treatment of inner ear disorders. Its advanced product candidate, AM-101, is in Phase III clinical development for acute inner ear tinnitus under a special protocol assessment (SPA) from the United States Food and Drug Administration.
Receive News & Ratings for Auris Medical Holding AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Auris Medical Holding AG and related companies with MarketBeat.com's FREE daily email newsletter.